Nomura Asset Management CO LTD Karuna Therapeutics, Inc. Transaction History

Nomura Asset Management CO LTD

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 03, 2023	BUY	$164.66 - $218.08 $392,384 - $519,684	2,383 Added 28.04%	10,883 $1.84 Million
Q4 2022 Feb 14, 2023	BUY	$191.53 - $236.82 $515,024 - $636,808	2,689 Added 46.27%	8,500 $1.67 Million
Q3 2022 Nov 10, 2022	BUY	$123.79 - $277.42 $719,343 - $1.61 Million	5,811 New	5,811 $1.31 Million
Q2 2022 Aug 12, 2022	BUY	$93.97 - $143.33 $0 - $0	0 New	0 $0
Q1 2022 May 13, 2022	BUY	$98.9 - $132.37 $0 - $0	0 New	0 $0
Q4 2021 Feb 01, 2022	BUY	$110.64 - $159.4 $0 - $0	0 New	0 $0
Q3 2021 Nov 12, 2021	BUY	$101.2 - $125.87 $0 - $0	0 New	0 $0
Q2 2021 Aug 06, 2021	BUY	$107.45 - $135.95 $0 - $0	0 New	0 $0
Q1 2021 May 14, 2021	BUY	$95.46 - $133.08 $0 - $0	0 New	0 $0
Q4 2020 Feb 12, 2021	BUY	$75.23 - $109.23 $0 - $0	0 New	0 $0
Q3 2020 Nov 12, 2020	BUY	$71.31 - $109.74 $0 - $0	0 New	0 $0
Q2 2020 Aug 13, 2020	BUY	$62.14 - $117.21 $0 - $0	0 New	0 $0
Q1 2020 May 14, 2020	BUY	$60.41 - $115.92 $0 - $0	0 New	0 $0
Q4 2019 Feb 13, 2020	BUY	$11.44 - $123.99 $0 - $0	0 New	0 $0

332K

Ticker KRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,965,000
Description
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...

Get notified when there are updates to the investment portfolio of Nomura Asset Management CO LTD, based on Form 13F filings with the SEC.

Stay updated on Nomura Asset Management CO LTD with notifications on news.